Delaware | 001-32335 | 88-0488686 | ||
(State or other jurisdiction | (Commission | (IRS Employer | ||
of incorporation) | File Number) | Identification No.) | ||
11388 Sorrento Valley Road, San Diego, California | 92121 | |||
(Address of principal executive offices) | (Zip Code) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure | ||||||||
Item 9.01 Financial Statements and Exhibits | ||||||||
SIGNATURES | ||||||||
EX-99.1 |
Exhibit No. | Description | |
99.1
|
Slide 10 of the January 2011 Presentation. |
Halozyme Therapeutics, Inc. |
||||
March 8, 2011 | By: | /s/ Kurt A. Gustafson | ||
Kurt A. Gustafson | ||||
Vice President and CFO | ||||
Halozyme Product Pipeline |
U0X)9@FW
M9W8"@7=78`:J='P7TWQ$!WV]QG/4QPS6AQ!1EWW+-D'E8(-_`#/AIUE\\(!#
MY$/,$`.60&!7(%1"555B\W[FQG;R%U_6M40)EW_;M5-DN#5%%8`H,@/5@$-\
M0`PU(`CE,WCLTP)XQ`?Q(O*)G]1-JIA=`MV4)ZR!`5T![
M#Z1C];!?ME6"=6=6*'@[*NA+:O5R7Q<#J)B*,7!+"/%R;Y!@"+/2A[G$"1&%?'-?*+4063A^4E<07A@#,A"(8Z"*J*@$
M:0=_;<=QOE1_4%:!+B!=TKB*,0"`=N@?55(N?R%#+P%PN*1'LI,-K+-N]4!@
M/,0'>L9Z*: FVP@`0Z)*Z6H6$8
MC3LGQGK4MP]%@1,=@L`Y'K6W#S'AB3C$X3ELR;-$<2)E?Z!=E%C@`(0F5*$)
ME84L:$"#392"'=9XPAJ6D8ULY"`''."`&;1@B%".,A'50V5)_Z3*/$2A;VV@
M(=!L* F7-!TNT.`JH$,8\4SU38I:AW$F#XW:_
M#0@K$S/^O4T#Q*4U6%J69A*$EGL["74X=Y#2/>X2AWC""P[QRN[;KWE_>.`K
M[ME[#S[B>Q<\WC=N>,`S7O"84WSA`R0_^"8_D`&RH*",F*".("JH.*9J^AT(?"8))"T:T!(6
M]`.:@(`7.!!^*:L?R1:"0Y""B(-LX08-&)H)&(
M\E"*-0S^8A&'2,4HTO"*+J3B#ZNH11IN489+)*,/GXC&*1IQBVUTXQOA&$
AR`"!UD`0!@
M`:(`!;@N"CPA8=`@8<:P87Y@`1ZM3QQ`3%`@"T3`>T@O],IF3U"!!?YE&F(F
MTIX077[^``6B0-),Y0=^Y6YN;SZ\YQ2]1P14400L@14MX15A,19A,1_\(!_J
MX19Q$1?#81=YL1=]D1?_X`^"(`ARH1B-\1ASP124<1F7<16<\1FA$0:D<1JI
M$0;JX!JQ$1L=H0X<%H(V'0E$04+DP$'#I-"H>$#]F,T:*`:,P`!-U@D
MKK0`&D`'B:B(B[AV&J`'C=B(<2")DTB);<,.DS`)EXB)FT@GG5@W>=,(H2B*
MHSB*)&"*I@@HCZ"*J[B*=_`(D7`'L!@)LTB+M4B+F1`)BM("N\B+O(@'OPB,
M>-`.H-`.Q=@.GH.,R:B,!@`ZK((-HT"`T2B-!7%<)H$AU4@0(5$0>8"&&N%W
M!"$"I;,7&"92XCB->7$<+;(T5L<7J$!G`6@1S!$:H6$)2Q,S$'`.QV%M,7$/
MT)*/D#4#TS`'`D"0!6F0!6DM":F0A:`"@``(#>F0$2F1#GG^`Q5Y`X-B#DF@
MD4E`!!WID1\Y"B$IDB%)#B5IDAZ`DAY`#2O)DBR)!2\)DS$IDS,)*C4)*JJ`
MDSAI!SG)DZHP"#\)E$$9E'%A""70*EYPCDFIE'4!`64P`3H$)DLIE3A!4#>`
M!J[C%^@TE:X4!0+P+[S!&U\IEJI!EF59EK6`EFFIEFN9ECA8"T(A%!8@EW-)
MEW19"7>)EWF9E[]0";_@EW\)F(!Y!(/9`8E@F-B`#8:IF(O)F(WIF(_9F)[3
M``Q`$5MIF9
5C$;WX/'_TBVPQH!C:>CJ9Z:/!I((YJL83%Q3$'
MGN`_PD&\#E,-E88*O],&*/`#K=<)E\=*\+5='50[WX1?UL0"NL9T#^,#6>R"
M[9(`KVZ#Y"I-)0@];@&MT%<]`&;BP8A.$'94!0UP4A+,`-DY`FSMXF;A(G
MW-")$M`(?,(G&&D.B`(%C+(HDQ(IEX(IG6(`Y5[NIP(,-J`JD_N,=OZM66=I
MJ9'2)C,,-MC@RW2&!3'H+])<&H+..(@8;?`O#CZ>4<`"0MC^46.B)#$!?&-R
M#U*73S3$3!<;O@4*WA=@+Q\:9L'+P[/7,0MP_2E-4!]-:Q'6T@"FU0'N2QK-#Z
M'O5!'_>A'P'R'U50!0=R(#V+#7#@[MAI0-GH=FZG7\Q$;4N3MEN?)"4Q=E:$
M(;K'J#"O)&BP&??@"4$=JD.-@S=8]ZI1]WD/EW#Y$W39%%(!^%*1%5C1F.E@
MF%MQ%HE/#PV`"3;PLUD/^9<)`7I(A&6@`J9Z#C/`!9O/^9WO^5P@WJ$O^J-/
M^J4?WGE@^FYG1:J/^ET_`^*P`9'^+_N768]1,ONWC_NYK_N[S_N][_N_#_S!
M+_R6*@)#8/S'3V+)K_S)/P0R4`\A5@]#L/S33_W)#_W*C_S-'_TC)OW1[_PR
M._?GR97G
M@JYE=E&P7]8%TN0A`C28KPJR*2$:$$`"?1M&$O3G`P"T8=D#^0,WDB`>
M3:B``-*,P`LT``AS(000XD6P!`"!)U1$X!P2&+9*HI"5/.`[WWFX(;_[/8Y_
M`_R+K1@XP0MN\(++P@L*7[C"8^#P;L2@&Q*?^,1/O`DE8#SC&"^%&SKN<3>X
M(^0B#[D+2F[RD[N@!RGO`
]%@`8(?4)C&$^8\F2Z!!`C>K3>4@%,1
M]3*R6("/'W#W`XTLRG!FUH&BR**(+(`5:`%/BD`!C64Y=Y:A++(P6:!"<.=C
MA&6CF$/Z".!%8;>46`C8@2Q0`$^@4GT8X=THNLCC^?A'90%!^6E"!<#\_6""
M_V/\[[EG^LB%/@A80'VP`8$)1.`&&-C`#21-'.(`P00I6$$*3@V#&;3:+CC8
M00XZ81=B$V'96%%"$Y[0"E906]K8MH=>[`&&,93A'N8F-[O^T0*'.-3;#@&'
M#!_^\(>%H\`K*%!$(QX1B44<@"T&T$0G/A&*3YR,Y3!G/RM>47,`$H@?FG6.
ME/B!1/@;";Q8T!((X.<@MDE(LVPR`Q$DY%]\0,4"(!`%\\0$%7D@44NB,`-T
MG0R+@11-&:@C`5,)$I&:087ORG"\1+9F!I'TT20G"21-#$,3F=3D)C,Y#C@L
M*4E0$B652%DE*Q4%E46)P2J[T4I7OK(I9I+E+-'T)C,'%6-RNI$;,U`&TR`,
M%
MC%KE-JA`%RK6'D7@&R5R*3DC':+A`]PPL11;L1:K`W.P3!J[L1*0`1[[L2`;
MLB(KLH#0329[LB<+!2J[LBS;LBH;3S!;3S([LS0[LPQPLSB;LSFK"#RK"';0
MLP<5M`4%#$1;M$9[M$9K`TJ[M$H[")B07S:`#7N0KPWA'I+T$+]$%(4T/`$X
M-U1W#46``@*A9WQ*'3QB6-`!'##3!FS;MF[[MG#;!K@PMW1;MW9[MS0D#7D+
M1-(P1'[[MT,$#H([N(1;N.!0#(B;N(I;#%/$N%;TN(];!9([N91;N99[N9@K
MN=&PN9S^V[F>^[G1T`"B&[JB6[JFVP#V@`G1,`A!0+4,X1*%L8-U$V6EE$K8
M@0JQHQ!/5;;&(0$^$+"3%!E\-KS$6[S&>[S':P%\-CZ>T+S.^[S0V[P$-+W4
M*T!D<+W8F[W:N[W9\J:%))Y^$,DHIIZ2R2BNOQ#)++;?DLDLOOP0S3#'')+-,
M,\]$,TTUTUQ!B*VBD,6'$>:DLTX[[\0S3SWWY+-//_\$-%!!!_4S)D,/1311
M11=EM%%''X4T(D&4J4"K*"8H8QI--^6T4T\_!35444
?FMJ
M8G.&FYBKWFFT)$"`GR[`!\?,PPB2K7,